Political and Legislative Risk: How Policy Shapes Healthcare Value

Introduction

Healthcare is the most politically regulated sector in the US economy. Roughly half of all healthcare spending flows through government programs, which means that legislative and regulatory decisions directly affect revenue for nearly every healthcare company. A single CMS rule change can shift margins across an entire sub-sector. A new law can restructure the competitive dynamics of a $600 billion pharmaceutical market. An executive order can reshape the regulatory approval process. No other coverage group faces this level of policy exposure, and healthcare bankers must understand how to incorporate political risk into their analysis.

The Inflation Reduction Act (IRA), signed in August 2022, represents the most significant change to US drug pricing policy in decades. Its core provisions affect pharma and biotech valuations directly:

Medicare Drug Price Negotiation (IRA)

Beginning in 2026, Medicare can negotiate prices for a select number of high-spend drugs that have been on the market for at least 7 years (small molecules) or 11 years (biologics) without generic or biosimilar competition. The number of drugs subject to negotiation increases from 10 in the first year to 20 per year by 2029. Maximum Fair Prices are capped at 75% of the non-federal average manufacturer price for drugs 7-11 years post-approval, declining to 40% for drugs 16+ years post-approval.

The IRA's valuation impact operates through several channels. Revenue reduction on negotiated drugs reduces the terminal value of products nearing LOE. Behavioral incentives push pharma companies toward biologics (which have an 11-year safe harbor vs. 7 years for small molecules) and toward launching new indications earlier. M&A implications increase the premium on early-stage pipeline assets, since earlier-stage drugs are further from negotiation eligibility.

Beyond major legislation, the Centers for Medicare & Medicaid Services (CMS) issues annual updates to reimbursement rates that directly affect margins in healthcare services, devices, and pharmaceuticals. These updates are technically administrative (not legislative), but their financial impact is substantial.

Key annual CMS actions include the Physician Fee Schedule update (affects physician services reimbursement), OPPS/ASC updates (outpatient and ambulatory surgery center payment rates), IPPS updates (inpatient hospital payments), and Medicare Part D formulary and coverage changes. Each update involves proposed rules, public comment periods, and final rules, creating a predictable calendar of reimbursement uncertainty.

For healthcare services companies, a 2-3% cut to the Medicare physician fee schedule directly reduces revenue per Medicare visit. For a company with 40% Medicare payer mix, a 3% Medicare rate cut reduces total revenue by approximately 1.2%, which can flow directly to EBITDA given the high fixed-cost nature of healthcare services operations.

Healthcare policy is a perennial campaign issue, and election cycles create meaningful valuation uncertainty across sub-sectors. The specific risks shift with each cycle, but the structural pattern is consistent: campaign rhetoric creates stock volatility, legislative proposals create modeling uncertainty, and actual legislation (when it passes) forces revaluation of affected companies.

Political risk in healthcare is best modeled through scenario analysis and sensitivity tables, not through discount rate adjustments. The reasons are practical: political outcomes are discrete events (a law passes or it doesn't), not continuous risks, and different policy outcomes affect different revenue streams in specific, quantifiable ways.

In practice, healthcare bankers build scenarios around pending legislation or regulatory proposals. A pharma valuation might include a "base case" assuming current law, a "reform case" assuming expanded price negotiation, and a "severe case" assuming broader pricing controls. Each scenario has different revenue trajectories for affected products, and the probability-weighted average of the scenarios produces the valuation.

This approach is more useful than simply increasing the WACC by 50-100 basis points for "political risk," because it forces the analyst to think specifically about which products are affected, by how much, and when. It also produces a range of outcomes that is valuable for advising clients on transaction pricing and risk allocation.